Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure

NCT04205799 ↗

Phase 2 Completed 57 enrolled Centre Francois Baclesse

NaSingle-groupOpen-labelTreatment

Summary

Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment.

Timeline

Start: 2020-01-15
Primary completion: 2023-01-15
Completion: 2023-01-15

Publications

Coquan E, Brachet PE, Licaj I, Leconte A, Castera M, Lequesne J, Meriaux E, Bonnet I, Lelaidier A, Clarisse B, Joly F. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure. BMC Cancer. 2021 Sep 25;21(1):1054. doi: 10.1186/s12885-021-08758-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cabozantinib	Small molecule	60 mg	Oral

Indications

No indication recorded.